<font id="drdzl"></font>

            <font id="drdzl"></font>

            <pre id="drdzl"><address id="drdzl"></address></pre>

              您的位置:易推廣 > 化工原料 > 化學試劑 > 分析試劑 > 武漢艾美捷科技有限公司 > 產品展示 > 生化試劑 > 附文獻丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介紹

              產品展示

              附文獻丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介紹

              點擊次數:0發布時間:2023/3/23 16:48:02

              附文獻丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介紹

              更新日期:2023/3/23 16:48:02

              所 在 地:中國大陸

              產品型號:

              簡單介紹:9H10單克隆抗體與小鼠CTLA-4(細胞毒性T淋巴細胞抗原-4)反應,也稱為CD152。CTLA-4是由Ctla33基因編碼的4 kDa細胞表面受體,屬于Ig超家族的CD28家族。

              優質供應

              詳細內容

               The 9H10 monoclonal antibody reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the Ctla4 gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade. The 9H10 antibody has been shown to promote T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding.

               

              9H10單克隆抗體與小鼠CTLA-4(細胞毒性T淋巴細胞抗原-4)反應,也稱為CD152。CTLA-4是由Ctla33基因編碼的4 kDa細胞表面受體,屬于Ig超家族的CD28家族。CTLA-4在活化的T和B淋巴細胞上表達。CTLA-4在結構上與T細胞共刺激蛋白CD28相似,并且兩種分子都與B7家族成員B7-1(CD80)和B7-2(CD86)結合。配體結合后,CTLA-4負調節細胞介導的免疫反應。CTLA-4在誘導和/或維持免疫耐受、胸腺細胞發育和保護性免疫調節中發揮作用。CTLA-4在免疫下調中的關鍵作用已在CTLA-4缺陷小鼠中得到證實,由于淋巴組織增生性疾病的發展,這些小鼠在3-5周齡時死亡。CTLA-4是一組通過免疫檢查點阻斷作為癌癥治療靶點的抑制受體。9H10抗體已被證明通過阻斷CTLA-4與B7共受體的結合來促進T細胞共刺激,從而允許CD28結合。

              21.png

              艾美捷InVivoPlus抗小鼠CTLA-4 (CD152) #BP0131、#BP0032規格:

              同種型 敘利亞倉鼠IgG

              推薦的同種型對照 體內加多克隆敘利亞倉鼠 IgG

              推薦的稀釋緩沖液 體內純 pH 7.0 稀釋緩沖液

              免疫原 小鼠CTLA-4-人IgG1融合蛋白

              報告的應用程序 體內CTLA-4 體外中和 CTLA-4 中和

              蛋白質印跡

              配方 PBS,pH 7.0

              不含穩定劑或防腐劑

              內毒素* <1EU/mg (<0.001EU/μg)

              通過LAL凝膠凝血測定法測定

              集合體* <5%

              由 DLS 確定

              純度 >95%

              由 SDS-PAGE 決定

              無 菌 0.2 μM 過濾

              生產 從無動物設施中的組織培養上清液中純化

              純化 蛋白 G

              里德 AB_10950184

              分子量 150 千達

              小鼠病原體檢測* 外切粒菌/鼠痘病毒: 陰性 漢坦病毒: 陰性 K 病毒: 陰性乳酸脫氫酶升高病毒: 陰性 淋巴細胞性脈絡叢腦膜炎病毒: 陰性小鼠腺病毒: 陰性小鼠巨細胞病毒: 陰性小鼠肝炎病毒: 陰性小鼠分鐘病毒: 陰性小鼠諾如病毒: 陰性小鼠細小病毒: 陰性

              小鼠輪狀病毒:肺支原體陰性:陰性 小鼠肺炎病毒:陰性 多瘤病毒:陰性呼腸孤病毒篩查:陰性 仙臺病毒:陰性 泰勒鼠腦脊髓炎:陰性

              存儲 抗體溶液應以4°C的儲備濃度儲存。 不要凍結。

               

              InVivoPlus抗小鼠CTLA-4 (CD152) 部分文獻引用:

              in vivo CTLA-4 neutralization

              Hervieu, A., et al. (2013). "Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth" J Invest Dermatol 133(2): 499-508.

               

              in vivo CTLA-4 neutralization

              Goding, S. R., et al. (2013). "Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma" J Immunol 190(9): 4899-4909.

               

              in vivo CTLA-4 neutralization

              Waitz, R., et al. (2012). "Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy" Cancer Res 72(2): 430-439.

               

              in vivo CTLA-4 neutralization

              Balachandran, V. P., et al. (2011). "Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido" Nat Med 17(9): 1094-1100.

               

              來源:https://www.amyjet.com/products/BXC-BP0131-5mg.shtml

              聯系我們

              聯系人:譚美

              點擊查看聯系方式

              企業檔案

              • 會員類型:免費會員
              • 工商認證: 【已認證】
              • 最后認證時間:
              • 法人:
              • 注冊號:
              • 企業類型:代理商
              • 注冊資金:人民幣萬

              script>
              在線咨詢

              提交

              国产三女人间水蜜桃叠罗汉_精品五月天六月花一区二区_狠狠噜天天噜日日噜无码_亚洲精品国产自在久久出水